Prediction and Treatment for Cancer Immunotherapy Induced Myocarditis
癌症免疫治疗引起的心肌炎的预测和治疗
基本信息
- 批准号:10217416
- 负责人:
- 金额:$ 18.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2022-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAnimal ModelAnti-Inflammatory AgentsAutoimmuneBackBiological MarkersBladderBlood Chemical AnalysisBlood CirculationBlood specimenBortezomibBreastCTLA4 geneCancer PatientCardiacCardiotoxicityCardiovascular systemCellsClinicalClinical TrialsDiagnosisDisseminated Malignant NeoplasmElectrocardiogramEnrollmentEvaluationExhibitsFDA approvedFemaleGenomic approachGoalsHeartHistologyHodgkin DiseaseImmuneImmune checkpoint inhibitorImmune systemImmunologic MarkersImmunosuppressionImmunotherapyImpairmentInfiltrationInflammationInflammatoryIntravenousInvestigationKidneyKineticsLifeLiverLungLymph Node of Head, Face and NeckMalignant NeoplasmsMalignant neoplasm of urinary bladderMedicalMessenger RNAMetastatic Neoplasm to the LungMusMyocarditisNF-kappa BNivolumabNon-Small-Cell Lung CarcinomaNormal tissue morphologyOrganOvaryPD-1 inhibitorsPathogenesisPathway AnalysisPatientsPeptidesPrecision therapeuticsPredictive ValuePrevalenceProductionPublishingRNARenal Cell CarcinomaRenal carcinomaReportingResearchSafetySensitivity and SpecificitySignal PathwaySignal TransductionSkinSmall Interfering RNASmall RNASteroidsSystemT-LymphocyteTestingTherapeutic EffectTissuesToxinTreatment EfficacyTroponinTumor Immunityanti-PD-L1anti-PD1 therapyanti-canceranticancer treatmentautoimmune arthritisbasebody systemcancer cellcancer immunotherapycancer therapyclinical practicecohortcytokinedesignearly detection biomarkersexosomeexperienceheart functionimmune checkpointimmune-related adverse eventsimprovedipilimumabknock-downmacrophagemalemelanomamouse modelnanonanoparticlenanoparticle deliverynanotherapeuticnew technologynovelnovel strategiesnovel therapeutic interventionp65pembrolizumabpotential biomarkerpredictive markerprogrammed cell death ligand 1programmed cell death protein 1siRNA deliveryside effectsuccesstranscriptome sequencingtranscriptomicstumor microenvironment
项目摘要
Abstract
In the past 10 years, the FDA has approved 6 checkpoint inhibitors and quickly expanded indications from
melanoma and non-small cell lung cancer to Hodgkin lymphoma, kidney, and bladder cancer. Moreover, there
are more than 150 ongoing clinical trials on PD-1 inhibitors treatment alone. Despite the anti-cancer benefits,
immunotherapy associated immune related adverse events affect a broad spectrum of organs, including heart.
Current diagnosis in clinical practices are troponin test and electrocardiograms, which, however, lack of
necessary sensitivity and specificity to myocarditis. Accordingly, in Specific Aim 1, we seek to identify
transcriptomic (RNAseq/MirSeq) biomarkers that may have predictive value for checkpoint inhibitor treatment
induced myocarditis. In this specific aim, we will be focused on patients who have developed autoimmune
myocarditis after receiving checkpoint inhibitor treatments and have blood samples banked. Such patients
provided an opportunity to identify new associative and predictive biomarkers that can serve as guideposts for
the implementation of new therapeutic approaches to suppress the inflammatory drivers of cardiotoxicity. For
medical management of immune Checkpoint Inhibitors associated myocarditis, current practices of subscribing
steroids expose patients to immune suppression systemically. In Specific Aim 2, we will evaluate a new anti-
inflammatory peptide-based nanoparticle system for delivering siRNA against NF-κB to manage myocarditis
induced by immune checkpoint inhibitors. Different from currently existing approaches, the new technology
proposed in Specific Aim 2 would enable anti-inflammation treatment delivery only to inflamed region in the heart.
Moreover, the testing agent has known anti-cancer effects. Therefore, the success of Specific Aim 2 could
provide precision treatment delivery and minimize systemic off-target side effects.
摘要
在过去的10年里,FDA已经批准了6种检查点抑制剂,并迅速扩大了适应症
黑色素瘤和非小细胞肺癌到霍奇金淋巴瘤、肾癌和膀胱癌。此外,还有
仅PD-1抑制剂治疗就有150多项正在进行的临床试验。尽管有抗癌的好处,
免疫治疗与免疫相关的不良事件影响广泛的器官,包括心脏。
目前临床上的诊断是肌钙蛋白试验和心电图,但缺乏
对心肌炎的必要敏感性和特异性。因此,在具体目标1中,我们试图确定
可能对检查点抑制剂治疗有预测价值的转录(RNAseq/MirSeq)生物标记物
诱发性心肌炎。在这个特定的目标中,我们将重点关注已发展为自身免疫的患者。
接受检查点抑制剂治疗后的心肌炎,并将血样存入银行。这样的病人
提供了一个机会来确定新的联合和预测性生物标记物,这些标记物可以作为
实施新的治疗方法以抑制心脏毒性的炎症驱动因素。为
免疫检查点抑制剂相关性心肌炎的医疗管理,目前的订阅做法
类固醇使患者全身暴露在免疫抑制之下。在具体目标2中,我们将评估一种新的反
以炎性多肽为基础的纳米系统携带针对NF-κB的小干扰RNA治疗心肌炎
由免疫检查点抑制剂诱导。与目前现有的方法不同,新技术
在特定目标2中提出的将使抗炎治疗仅能输送到心脏发炎的区域。
此外,该测试剂具有已知的抗癌作用。因此,《特定目标2》的成功可能
提供精确的治疗交付,并最大限度地减少系统性偏离目标的副作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hua Pan其他文献
Hua Pan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hua Pan', 18)}}的其他基金
Prediction and Treatment for Cancer Immunotherapy Induced Myocarditis
癌症免疫治疗引起的心肌炎的预测和治疗
- 批准号:
10645593 - 财政年份:2022
- 资助金额:
$ 18.69万 - 项目类别:
Mitigate cisplatin induced acute kidney injury through preservation of vasculature and proximal tubule
通过保护脉管系统和近端小管减轻顺铂引起的急性肾损伤
- 批准号:
10644372 - 财政年份:2021
- 资助金额:
$ 18.69万 - 项目类别:
Mitigate cisplatin induced acute kidney injury through preservation of vasculature and proximal tubule
通过保护脉管系统和近端小管减轻顺铂引起的急性肾损伤
- 批准号:
10661849 - 财政年份:2021
- 资助金额:
$ 18.69万 - 项目类别:
Mitigate cisplatin induced acute kidney injury through preservation of vasculature and proximal tubule
通过保护脉管系统和近端小管减轻顺铂引起的急性肾损伤
- 批准号:
10209816 - 财政年份:2021
- 资助金额:
$ 18.69万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 18.69万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 18.69万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 18.69万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 18.69万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 18.69万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 18.69万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 18.69万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists